louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03114579: Evaluation of the Measurement of Cardiac Output by the NEXFIN HD Monitor in Peroperative
Official title: Evaluation of the Measurement of Cardiac Output by the NEXFIN HD Monitor in Peroperative
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiac Output
Peroperative
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2017-04-14
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Continuous perioperative cardiac output (DC) and blood pressure (PA) monitoring contributes to hemodynamic stability and ensures adequate perfusion pressure, resulting in a reduction in morbidity and mortality and length of hospital stay.

The monitors usually used in perioperative are either semi-invasive and difficult for calibration (oesophageal Doppler) or invasive (arterial catheter).

The Nexfin HD allows these two measurements and it is completely non-invasive, remains to validate its use in peroperative.


Eligibility criteria: Inclusion Criteria:

* Adult patients candidate for surgery under general anesthesia requiring oesophageal Doppler or arterial catheter hemodynamic monitoring.

Exclusion Criteria:

* Patients with cardiac and thoracic surgery,
* patients for whom access to the head is impossible,
* facial trauma patients,
* patients with aortic malformation, dilation or coarctation,
* patients with aortic dissection,
* patients with vascular surgery with aortic clamping,
* patients with a tumor, stenosis or varices of the esophagus,
* patients with severe oesophagitis,
* patients with thoracic radiotherapy
* patients under guardianship or curatorship or deprived of liberty.

Primary outcomes:
measure: Overall survival defines as the time between the date of surgery and death or date of last news
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens Picardie
state: Picardie
Study officials:
References:
Clinical trial NCT05225779: The Effects of Sevoflurane and Desflurane on QT Interval Measured With Cardiac Electrophysiological Balance Index
Official title: A Prospective Randomized Comparison of the Effects of Sevoflurane and Desflurane Anesthesia on QT Interval Measured With Cardiac Electrophysiological Balance Index
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sevoflurane
Desflurane
QT Interval
Electrophysiological Balance Index
Lead sponsor: Ankara City Hospital Bilkent
Sponsor class: OTHER
First posted: 2022-02-07
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The primary aim of this study is to compare the effects of sevoflurane and desflurane on the QT interval. The secondary aim of this study is to compare the effects of drugs used in the induction and maintenance of anesthesia on the QT interval by calculating the Bazzet formula and iCEB.


Eligibility criteria: Inclusion Criteria:

1. ASA I-II-III risk group
2. the operation time is longer than 1 hour in the Urology department.

Exclusion Criteria:

1. bundle branch block in preoperative ECG,
2. Non-sinus heart rhythm,
3. QT length in preoperative ECG,
4. using drugs that cause known QT prolongation ( beta-blocker drugs using will be included),
5. development of malignant arrhythmia that will disrupt hemodynamics in the intraoperative period,
6. patients with electrolyte disorders,
7. patient refusal -

Primary outcomes:
measure: QTc T0
timeFrame: Baseline, preoperative
measure: QTc T1
timeFrame: During surgery (at the time of the anesthesia induction)
measure: QTc T2
timeFrame: During surgery (at the time of MAC reached 0,6)
measure: QTc T3
timeFrame: During surgery (at the time of MAC reached1)
measure: QTc T4
timeFrame: During surgery (at the time of MAC reached 1,3)
measure: QTc T5
timeFrame: During surgery (at the time of MAC reduced 0,3)
measure: iCEB T0
timeFrame: Baseline, preoperative
measure: iCEB T1
timeFrame: During surgery (at the time of the anesthesia induction)
measure: iCEB T2
timeFrame: During surgery (at the time of MAC reached 0,6)
measure: iCEB T3
timeFrame: During surgery (at the time of MAC reached 1)
measure: iCEB T4
timeFrame: During surgery (at the time of MAC reached 1,3)
measure: iCEB T5
timeFrame: During surgery (at the time of MAC reduced 0,3)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: ankara ch bilkent
name: ışıl karabeyoğlu
role: PRINCIPAL_INVESTIGATOR
affiliation: Ankara CH bilkent
name: betül güven aytaç
role: STUDY_CHAIR
References:
Clinical trial NCT03893279: Perception of Smell and Taste During Antibiotic Treatment
Official title: Perception of Smell and Taste During Antibiotic Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infectious Disease
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2019-03-28
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient meeting the eligibility criteria followed in the department of Infectious and Tropical Diseases of the Croix Rousse Hospital of the Civil Hospitals of Lyon

Brief summary: Antibiotic use may be associated with effects on the perception of smell and taste. These effects are poorly known. The mechanisms can be very diverse, and the effect can be very variable depending on the type of antibiotic used, the dose, and the duration.

The aim of this study is to analyze the perception of the taste and olfactory capacities of patients, during an antibiotic treatment.


Eligibility criteria: Inclusion Criteria:

* Major patient
* Patient with bacterial infectious disease requiring antibiotic treatment.
* Having been informed about the study and not having opposed to participate

Exclusion Criteria:

* Patient under legal protection
* Patient refusing to participate

Primary outcomes:
measure: Questionnaire on Perception of taste
timeFrame: Time of antibiotic treatment (maximum 6 months)
measure: Questionnaire on Perception of smell
timeFrame: Time of antibiotic treatment (maximum 6 months)
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Department of Infectious and Tropical Diseases of the Croix Rousse Hospital of the Civil Hospitals of Lyon
Study officials:
References:
Clinical trial NCT06569979: The Knowledge Gaps of Amputee Rehabilitation Course Content in Physiotherapy Curriculum
Official title: The Knowledge Gaps of Amputee Rehabilitation Course Content in Physiotherapy Curriculum According to International Classification of Functioning, Disability and Health (ICF)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Amputation
Rehabilitation
ICF
Lead sponsor: Akdeniz University
Sponsor class: OTHER
Collaborators: name: Hasan Kalyoncu University
First posted: 2024-08-26
Enrollment: 73
Sex: ALL
Minimum age (years): 25
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Academicians aged 25-80 and continued to teach amputee rehabilitation in different higher education institutions in Turkey were included in the study.

Brief summary: Understanding the knowledge gaps of amputee rehabilitation course content is essential for addressing these gaps. Identifying the course contents according to International Classification of Functioning, Disability and Health (ICF) can be a starting point for determining the gaps. This study aimed to investigate which amputee-specific ICF categories are underemphasized in the course content.

Detailed description: For understanding the knowledge gaps of amputee rehabilitation course content, a total of 59 amputee-specific ICF categories were asked to the academics whether these categories are present in the amputee rehabilitation course content. Academics were asked to answer "yes" or "no" to each question. Cochrane Q test was used to test for differences between the frequencies of ICF categories.

Sleep functions, high-level cognitive functions in the field of body functions, writing and handling stress in the activity sub-domain, most of the categories in the participation sub-domain and environmental factors were significantly underemphasized in the course content.This study identifies the knowledge gaps of amputee rehabilitation course content in physiotherapy curriculum.

Eligibility criteria: Inclusion Criteria:

* Academicians who continued to teach amputee rehabilitation in different higher education institutions in Turkey were included in the study.

Exclusion Criteria:

* Individuals who did not teach the whole course but contributed to only a part of it were not included in the study

Primary outcomes:
measure: Survey
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Antalya
country: Turkey
facility: Akdeniz University
Study officials:
affiliation: Akdeniz University Vocational School of Health Services
name: Hatice Gül
role: PRINCIPAL_INVESTIGATOR
References:
citation: Scholten I, Barradell S, Bickford J, Moran M. Twelve tips for teaching the International Classification of Functioning, Disability and Health with a view to enhancing a biopsychosocial approach to care. Med Teach. 2021 Mar;43(3):293-299. doi: 10.1080/0142159X.2020.1789082. Epub 2020 Jul 9.
Clinical trial NCT00888979: Pilot Study of Nicotine Replacement for Smoking Cessation During Pregnancy
Official title: Pilot Study of Nicotine Replacement for Smoking Cessation During Pregnancy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tobacco Use Disorder
Keywords: Smoking Cessation during Pregnancy
Nicotrol Inhaler
Lead sponsor: Hartford Hospital
Sponsor class: OTHER
Collaborators: name: UConn Health
First posted: 2009-04-28
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: We plan to examine the feasibility, acceptability, preliminary quit rates, overall nicotine exposure and adverse effects of the nicotine inhaler for smoking cessation in pregnancy.

Detailed description: Subjects in this pilot study are healthy pregnant women who wish to quit smoking. They will set a quit date and use the nicotine inhaler for 4 weeks. They will receive behavioral counseling in addition to the inhaler for 4 weeks.

Eligibility criteria: Inclusion Criteria:

* 13-26 weeks pregnant
* Smoking at least 5 cigarettes per day the preceding 7 days
* Motivated to quit smoking (at least 7 on a 10 pt. scale)
* Able to speak English
* Intend to carry pregnancy to term
* Stable residence

Exclusion Criteria:

* Current drug or alcohol abuse or dependence (other than methadone maintenance
* Twins or multiple gestation
* Unstable psychiatric disorder
* Unstable medical problems
* Known congenital abnormality
* High risk pregnancy

Primary outcomes:
measure: Number of Days of Inhaler Use
timeFrame: Baseline to 4 weeks
Secondary outcomes:
measure: Cartridge Use
timeFrame: Baseline to 4 weeks
measure: Change in Number of Cigarettes Used Per Day From Baseline to 4 Weeks.
timeFrame: Baseline to 4 weeks
Other outcomes:
Locations:
city: Hartford
country: United States
facility: Hartford Hospital
state: Connecticut
Study officials:
affiliation: UConn Health
name: Cheryl Oncken, MD MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04457479: APERIO® HYBRID Thrombectomy Device for Flow Restoration in Vessels of Patients Experiencing Acute Ischemic Stroke
Official title: APERIO® HYBRID Thrombectomy Device for Flow Restoration in Vessels of Patients Experiencing Acute Ischemic Stroke
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Stroke
Lead sponsor: Acandis GmbH
Sponsor class: INDUSTRY
First posted: 2020-07-07
Enrollment: 190
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with acute large vessel occlusion (stroke) treated with the APERIO® Hybrid(17/21) Thrombectomy Device.

Brief summary: This is a prospective, multicenter, single-arm, open-label, national Post-Market Clinical Follow-up study to collect comprehensive information on technical and clinical success and safety of the use of APERIO® Hybrid(17/21) Thrombectomy Device in clinical practice. APERIO® Hybrid(17/21) Thrombectomy Device will be used within its approved indication.

Detailed description: German APERIO® Hybrid Post- Market Clinical Follow-up Study

APERIO® Hybrid PMCF Study- Thrombectomy device for flow restoration in vessels of patients experiencing acute ischemic stroke

Study Type: prospective, multicenter, single-armed, open-label

Participants: 8 participating centers in Germany

PI: Dr. Christian Mathys, Evangelisches Krankenhaus Oldenburg, Germany

Estimated Enrolment: 190 patients treated with APERIO® HYBRID(17/21) Thrombectomy Device as a result of an acute stroke

Follow up: 3 months

Estimated Final Assessment: Mid to End of 2023

Eligibility criteria: Inclusion Criteria:

- All patients treated with APERIO® HYBRID and/or APERIO® Hybrid(17/21) Thrombectomy Device as a result of an acute stroke.

Exclusion Criteria:

* Patient age \< 18 years
* Pre stroke mRS ≥ 3

Primary outcomes:
measure: Technical success
timeFrame: until 24 hours after intervention
measure: Good clinical outcome at 90 days
timeFrame: 90 days after intervention
measure: Periprocural symptomatic intracranial hemorrhage (sICH):
timeFrame: until 24 hours after intervention
Secondary outcomes:
measure: Cerebrovascular events until hospital discharge:
timeFrame: between 24 hours after intervention and discharge from hospital
measure: Cerebrovascular events at 90 days
timeFrame: at 90 days
Other outcomes:
Locations:
city: Oldenburg
country: Germany
facility: Evangelisches Krankenhaus Oldenburg
Study officials:
References:
Clinical trial NCT06995079: Comparıson Of The Effects Of Perıcapsulary Nerve Group Block (Peng Block) And Lumbar Erector Spına Plan Block (Lesp Block) On Postoperatıve Opıoıd Consumptıon
Official title: Comparison of the Effects of Pericapsular Nerve Group Block (Peng Block) and Lumbar Erector Spinae Plane Block (Lesp Block) on Postoperative Opioid Consumption in Geriatric Patients Undergoing Hip Fracture Surgery
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Pengblock
over65years
Lumbar Erector Spinae Plane Block
Hipfracture
Lead sponsor: Sakarya University
Sponsor class: OTHER
First posted: 2025-05-29
Enrollment: 70
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim is to demonstrate that lumbar ESP block provides more effective postoperative analgesia than PENG block in geriatric patients with hip fractures, and reduces postoperative opioid consumption more than PENG block


Eligibility criteria: Inclusion Criteria:

* patients with hip fractures
* over 65 years old

Exclusion Criteria:

* long-term surgery
* Patients who do not want regional anesthesia
* bleeding disorder disease
* wound in the operation area

Primary outcomes:
measure: postoperative pain
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04489979: Analgetics vs Analgetics and Antibiotics for Pediatric Clinical and Sonographic Orchitis or Epididymitis
Official title: Analgetics vs Analgetics and Antibiotics for Pediatric Clinical and Sonographic Orchitis or Epididymitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epididymitis Orchitis
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2020-07-28
Enrollment: 72
Sex: MALE
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male children who were admitten to pediatric emergency department due to epididymitis or orchitis

Brief summary: Some children are admitted to pediatric emergency department due to epididymitis or orchitis. Some of them are treated by analgetics only whie some are treated by analgetics with antibiotics. The study will compare clinical presentation between groups and will compare pediatric urologic outpatient clinic follow up findings.

Detailed description: Some children are admitted to pediatric emergency department due to epididymitis or orchitis. Some of them are treated by analgetics only whie some are treated by analgetics with antibiotics. The study will compare clinical presentation between groups and will compare pediatric urologic outpatient clinic follow up findings.

Eligibility criteria: Inclusion Criteria:

* All children admitted to pediatric emergency department due to epididymitis or orchitis

Exclusion Criteria:

* No sonographic or laboratory exam
* Antibiotic treatment before diagnosis
* No outpatient follow-up
* Known urologic congenital malformations
* Admission to inpatient department or emergency surgery

Primary outcomes:
measure: Healing
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: H̱adera
country: Israel
facility: Hillel Yaffe medical center
state: Hadera
Study officials:
affiliation: Hillel Yaffe Medical Center
name: Erez Nadir, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lau P, Anderson PA, Giacomantonio JM, Schwarz RD. Acute epididymitis in boys: are antibiotics indicated? Br J Urol. 1997 May;79(5):797-800. doi: 10.1046/j.1464-410x.1997.00129.x.
Clinical trial NCT02984579: Line Probe Assay Evaluation Study
Official title: Multi-center Study to Assess the Non-inferiority of YD REBA MTB-MDR® and Hain GenoType® MTBDRplus V2 Line Probe Assays Compared to Hain GenoType® MTBDRplus V1
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multidrug-Resistant Tuberculosis
Isoniazid Resistant Pulmonary Tuberculosis
Rifampicin Resistant Tuberculosis
Pulmonary Tuberculoses
Lead sponsor: Foundation for Innovative New Diagnostics, Switzerland
Sponsor class: OTHER
Collaborators: name: Research Center Borstel
name: National Institute for Communicable Diseases, South Africa
name: Institute of Tropical Medicine, Belgium
First posted: 2016-12-07
Enrollment: 888
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study consisted of two phases. In phase 1, each site was sent a different set of 200 clinical isolates from the Research and Training in Tropical Diseases and Institute for Tropical Medicine collections (ITM).

In phase 2, samples from 274 patients recruited between Azerbaijan and Moldova were tested in Germany, while samples from 214 (locally-recruited) patients were tested in South Africa.

Brief summary: This is a multi-center, blinded study to determine the performance of the YD Diagnostic Corporation (YD) REBA MTB-MDR® and Hain Genotype MTBDRplus V2 kit in a total of 600 clinical isolates and 900 residual sputum samples from patients with symptoms of pulmonary TB (PTB) and at risk of drug resistance. All testing was done on stored, de-identified leftover samples.

The study involved three World Health Organization (WHO) Supranational Reference Laboratories with well-characterized strain collections and access to sputum samples with significant rates of drug resistance.


Eligibility criteria: Inclusion Criteria:

* Age over 18 years
* Informed consent
* Patients evaluated for pulmonary TB

Exclusion Criteria:

-

Primary outcomes:
measure: INH/RIF Resistance Detection
timeFrame: At the end of study 9-10 Months after the Study started
Secondary outcomes:
measure: Multi-Drug Resistant TB detection
timeFrame: At the end of study 9-10 Months after the Study started
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06403579: THE EFFECT OF VIRTUAL REALITY APPLICATION ON PAIN, ANXIETY, AND COMFORT DURING CURETTAGE/DILATATION
Official title: THE EFFECT OF VIRTUAL REALITY APPLICATION ON PAIN, ANXIETY, AND COMFORT DURING CURETTAGE/DILATATION: A RANDOMIZED CONTROLLED TRIAL
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Bleeding;Post D&C
PAIN, ANXIETY, AND COMFORT
Lead sponsor: Cukurova University
Sponsor class: OTHER
First posted: 2024-05-08
Enrollment: 80
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 49
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The problems experienced by women at the stage of deciding to have a miscarriage, during and after miscarriage differ and their anxiety levels vary. It was determined that women experienced fear, thinking that they would sin, guilt, regret and indecision at the stage of deciding to abort. methods are used to relieve the pain and anxiety caused by interventional procedures in patients in direct proportion to the development of technology. Virtual reality (VR), one of these methods, is an innovative, up-to-date and unique application, combining reality and imagination with fictional technology.There is no study in the literature on the application of SG during curettage/dilatation procedure. This study was conducted to determine the effect of SG application on pain anxiety and comfort during curettage/dilatation procedure.


Eligibility criteria: Inclusion Criteria:

* 15-49 years old,
* Termination ordered,
* Can speak and understand Turkish,

Exclusion Criteria:

* - Cognitive, effective and without any problem preventing communication,
* No psychiatric problems,
* Diagnosed with epilepsy (due to the risk that SG glasses may trigger epileptic seizures),
* Women who volunteer to participate in the study will be recruited.

Primary outcomes:
measure: virtual reality application
timeFrame: at 1 hour after curettage
measure: virtual reality application
timeFrame: at 1 hour after curettage
measure: virtual reality application virtual reality application
timeFrame: at 1 hour after curettage
Secondary outcomes:
Other outcomes:
Locations:
city: Adana
country: Turkey
facility: Seda Karaçay Yıkar
state: Sarıcam
Study officials:
References: